Futuximab

Cat. No.: HY-P99628: FAQs
Data Sheet

Molarity Calculator

Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity.

For research use only. We do not sell to patients.

CAS No. : 1310460-85-5

Size		Stock
1 mg		Get quote	Estimated Time of Arrival: December 31
5 mg		Get quote	Estimated Time of Arrival: December 31

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity^[1].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species

Chimeric

In Vitro

Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	NR6M cells
Concentration:	20 µg/mL
Incubation Time:	24 h or 48 h
Result:	Slightly reduced EGFRvIII levels in NR6M cells.

In Vivo

Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX)^[1]
Dosage:	50 mg/kg
Administration:	i.p.; twice weekly; for 5 weeks
Result:	Inhibited tumor growth in EGFRwt expressing xenograft model.

Clinical Trial

CAS No.

1310460-85-5

SMILES

[Futuximab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Purity & Documentation

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498. [Content Brief]

Futuximab Related Classifications

Inhibitory Antibodies

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Futuximab1310460-85-5EGFREpidermal growth factor receptorErbB-1HER1chimeric monoclonal antibodyantineoplastic activityEGFRvIIIInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks